AnHeart Therapeutics
Latest round
- Series B
Last raised
- Dec 2021
Total raised
- $76M
Investors
- 7
About AnHeart Therapeutics
Founded in 2018, and based in New York, US, AnHeart Therapeutics Inc. is a multinational clinical-stage biopharmaceutical business that creates treatments for cancer patients. The company was founded by its CEO, Junyuan Jerry Wang, and President Bing Yan. In April 2024, Nuvation Bio, Inc., Ltd. from Decheng Capital, China Merchants Capital, Cenova Ventures, and Innovent Biologics, Inc. Following the acquisition, AnHeart Therapeutics shareholders own 33%, and the stockholders of Nuvation Bio own 67% of Nuvation Bio on a fully diluted basis. AnHeart Therapeutics develops, creates, and commercializes biotechnology-based novel oncology medicines and treatments for patients suffering from cancer. As of 2024, the company’s product pipeline includes clinical-stage therapeutic cancer treatments such as taletrectinib (a ROS1 inhibitor) and safusidenib (a mIDH1 inhibitor). The treatments significantly enhance patient health by focusing on and attacking vital pathways in cancer cells.
Who invested in AnHeart Therapeutics
7 investors across 3 rounds
See all investors in AnHeart Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AnHeart Therapeutics
Who invested in AnHeart Therapeutics?
AnHeart Therapeutics has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AnHeart Therapeutics raised?
AnHeart Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did AnHeart Therapeutics last raise money?
AnHeart Therapeutics's most recent round on record is a Series B, in Dec 2021.
What does AnHeart Therapeutics do?
Founded in 2018, and based in New York, US, AnHeart Therapeutics Inc.
Where is AnHeart Therapeutics headquartered?
AnHeart Therapeutics is headquartered in New York, US.
Which VCs invest in companies like AnHeart Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AnHeart Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like AnHeart Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.